Q&M Dental Group (“Q&M”) plans to issue new SGD 3-year Senior Notes at an initial price guidance (“IPG”) of 4.35%. The new bond is expected to be issued on 3rd July 2025. Q&M indicated that the net proceeds will be used for general corporate purposes, including financing acquisitions and/or investments, business expansions, refinancing of borrowings, financing of working capital, and capital expenditure requirements. We wish to note that this new issuance is available only for accredited and institutional investors.
Established in 1996, Q&M is one of the biggest private dental groups in Singapore, with additional dental clinics in Malaysia. Additionally, Q&M is also a substantial shareholder of SGX-listed Aoxin Q&M Dental Group (c.32.8% ownership) which operates dental clinics and hospitals primarily in the north-eastern region of the People’s Republic of China (“PRC”). As of 31st December 2024, Q&M has 106 dental clinics in Singapore, 38 dental clinics in Malaysia, and Aoxin Q&M Dental Group Limited (“Aoxin Q&M”) has 16 dental centres in China.
For the full year of 2024 (“FY24”), gross revenue declined slightly by 1.1% year on year (“YoY”) to SGD 180.7m in FY24 (FY23: SGD 182.7m). This was due to their medical laboratory business following the expiry of their clinical laboratory service license. Q&M operates mostly within Singapore, with Singapore accounting for 92.6% of FY24 revenue (SGD 167.3m), and Malaysia with the remaining 7.4% (SGD 13.4m).
When considering only their core dental business, Q&M’s revenue grew marginally by 0.5% to SGD 173.8m in FY24 (FY23: SGD 173.0m) due to higher patient volumes in both Malaysia and premium service offerings.
Q&M also recorded an 18.0% YoY growth in net profit to SGD 13.1m in FY24 (FY23: SGD 11.1m). Net profit growth was mainly due to both lower employee benefits expenses and dental supplies expenses, of which the former is due to Q&M sharing administrative charges with their dentists.
In our view, Q&M is seen to have strong financials coupled with consistent core profits due to their strong market share within the Singapore dental care market. Even in a softening economic growth backdrop, we expect demand for dental care (an essential service) to remain resilient and sticky. Beyond FY25, Q&M’s plan to embark on regional M&A fueled expansion in Singapore and Malaysia serves as an upside for growth. Per management, the company plans to leverage inorganic growth to significantly grow their number of clinics and consolidate market leadership in FY25 and beyond - M&A has been mentioned as a primary reason for this issuance as well.
Q&M reported an 8.2% YoY decline in total debt to SGD 73.7m as of FY24 (FY23: SGD 80.3m) due to the repayment of bank loan principal in FY24. Consequently, net debt / equity improved to 36.3% in FY24 (FY23: 45.0%) giving the company a healthy buffer to their loan covenant of 200.0% net debt / equity for this bond issue. We expect this buffer to narrow after the debt issuance.
EBITDA interest coverage ratio improved to 7.1x as of FY24 (FY23: 6.6x) from both EBITDA growth and a decline in financing costs due to the falling interest rate environment. The company has a healthy buffer compared to their current loan covenant of 1.75x interest coverage ratio. Similarly, this buffer will narrow after the new debt issuance.
As for the debt maturity profile (before the new issuance), most of Q&M’s SGD 73.7m debt (c.88.2%) is due for repayment within 5 years. We think that financing needs are manageable considering 1) the strong cash position that Q&M currently has (FY24: SGD 34.3m), 2) the strong operating cash flow in the last few years (FY24: SGD 40.1m, FY23: SGD 33.3m, FY22: SGD 33.6m). Post-issuance, we expect a more front-loaded debt maturity, with the bulk of maturity in 2028.
Table 1: Comparing against peers
|
Issuance |
Ask Price |
Years to call |
Yield to Maturity |
|
QNMSP 10Jul2028 Corp (SGD)* |
100.00* |
3.00* |
4.35%* |
|
104.90 |
2.92 |
3.70% |
|
|
104.30 |
4.22 |
2.45% |
|
|
100.05 |
2.91 |
3.73% |
|
|
100.95 |
3.07 |
2.97% |
|
|
103.50 |
3.58 |
2.67% |
|
|
Sources: Bondsupermart, iFAST Compilations. Data as of 2 July 2025. *Yet to be issued |
|||
We expect Q&M’s credit profile to moderate after the debt issuance. That said, we remain positive on its profit outlook as their core dental business continues to grow, while further upside may come from its intended M&A expansion.
Given that the Dentistry industry is niche, noticeable non-rated bond peers would have to be from peripheral industries such as healthcare and the general Singapore bond market instead. When comparing the issuance to other suitable peers such as Thompson Medical and Singapore Medical Group, we note that the IPG of 4.35% seems rather attractive, especially against the latter. Outside of the healthcare space, Q&M’s IPG is still attractive when compared to SGD corporate bonds with a similar tenor (Table 1). That said, we expect the final price guidance (“FPG”) to adjust downwards from the IPG.
Considering Q&M’s credit profile and relatively attractive IPG, we recommend this issuance for investors that are comfortable with the near-term maturity.
Declaration: For specific disclosure, at the time of publication of this report, IFPL (via its connected and associated entities) hold a position in TMGSP 5.500% 31May2028 Corp (SGD). The analyst who produced this report holds a NIL position in the abovementioned securities.
Our podcast series, Yield Hunters, is available on Spotify, iTunes Podcasts and Google Podcasts. We share our thoughts on new bond issues and hold discussions on the fixed income space. Listen to our latest episode below and follow us!
All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.
Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).
iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.
Please note that only certain bond(s) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to FSM's prevailing policies and procedures. Please read our full disclaimers in the website.